Cargando…
Cardiotoxicity of Novel Targeted Hematological Therapies
Chemotherapy-related cardiac dysfunction, also known as cardiotoxicity, is a group of drug-related adverse events negatively affecting myocardial structure and functions in patients who received chemotherapy for cancer treatment. Clinical manifestations can vary from life-threatening arrythmias to c...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763613/ https://www.ncbi.nlm.nih.gov/pubmed/33322351 http://dx.doi.org/10.3390/life10120344 |
_version_ | 1783628059874689024 |
---|---|
author | Giudice, Valentina Vecchione, Carmine Selleri, Carmine |
author_facet | Giudice, Valentina Vecchione, Carmine Selleri, Carmine |
author_sort | Giudice, Valentina |
collection | PubMed |
description | Chemotherapy-related cardiac dysfunction, also known as cardiotoxicity, is a group of drug-related adverse events negatively affecting myocardial structure and functions in patients who received chemotherapy for cancer treatment. Clinical manifestations can vary from life-threatening arrythmias to chronic conditions, such as heart failure or hypertension, which dramatically reduce quality of life of cancer survivors. Standard chemotherapy exerts its toxic effect mainly by inducing oxidative stress and genomic instability, while new targeted therapies work by interfering with signaling pathways important not only in cancer cells but also in myocytes. For example, Bruton’s tyrosine kinase (BTK) inhibitors interfere with class I phosphoinositide 3-kinase isoforms involved in cardiac hypertrophy, contractility, and regulation of various channel forming proteins; thus, off-target effects of BTK inhibitors are associated with increased frequency of arrhythmias, such as atrial fibrillation, compared to standard chemotherapy. In this review, we summarize current knowledge of cardiotoxic effects of targeted therapies used in hematology. |
format | Online Article Text |
id | pubmed-7763613 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77636132020-12-27 Cardiotoxicity of Novel Targeted Hematological Therapies Giudice, Valentina Vecchione, Carmine Selleri, Carmine Life (Basel) Review Chemotherapy-related cardiac dysfunction, also known as cardiotoxicity, is a group of drug-related adverse events negatively affecting myocardial structure and functions in patients who received chemotherapy for cancer treatment. Clinical manifestations can vary from life-threatening arrythmias to chronic conditions, such as heart failure or hypertension, which dramatically reduce quality of life of cancer survivors. Standard chemotherapy exerts its toxic effect mainly by inducing oxidative stress and genomic instability, while new targeted therapies work by interfering with signaling pathways important not only in cancer cells but also in myocytes. For example, Bruton’s tyrosine kinase (BTK) inhibitors interfere with class I phosphoinositide 3-kinase isoforms involved in cardiac hypertrophy, contractility, and regulation of various channel forming proteins; thus, off-target effects of BTK inhibitors are associated with increased frequency of arrhythmias, such as atrial fibrillation, compared to standard chemotherapy. In this review, we summarize current knowledge of cardiotoxic effects of targeted therapies used in hematology. MDPI 2020-12-11 /pmc/articles/PMC7763613/ /pubmed/33322351 http://dx.doi.org/10.3390/life10120344 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Giudice, Valentina Vecchione, Carmine Selleri, Carmine Cardiotoxicity of Novel Targeted Hematological Therapies |
title | Cardiotoxicity of Novel Targeted Hematological Therapies |
title_full | Cardiotoxicity of Novel Targeted Hematological Therapies |
title_fullStr | Cardiotoxicity of Novel Targeted Hematological Therapies |
title_full_unstemmed | Cardiotoxicity of Novel Targeted Hematological Therapies |
title_short | Cardiotoxicity of Novel Targeted Hematological Therapies |
title_sort | cardiotoxicity of novel targeted hematological therapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763613/ https://www.ncbi.nlm.nih.gov/pubmed/33322351 http://dx.doi.org/10.3390/life10120344 |
work_keys_str_mv | AT giudicevalentina cardiotoxicityofnoveltargetedhematologicaltherapies AT vecchionecarmine cardiotoxicityofnoveltargetedhematologicaltherapies AT sellericarmine cardiotoxicityofnoveltargetedhematologicaltherapies |